Introduction
To date, the lack of a broadly accepted definition of drugresistant, refractory or intractable epilepsy has made it difficult to compare different studies about the subject. Recently, the International League Against Epilepsy (ILAE) appointed a task force under the Commission on Therapeutic Strategies to formulate a proposal for a consensus definition of drug-resistant epilepsy. The report has recently been published. 1 We considered it important to test this new definition in an epidemiological study aiming to investigate the following aspects of childhood epilepsy: response to antiepileptic treatment, risk of developing drugresistant epilepsy, clinical features of drug-resistant epilepsy and temporal evolution of drug resistant epilepsy.
Methods

Definitions and classification criteria
Seizures were considered unprovoked when they occurred without any known proximal precipitant. Epilepsy was defined as the occurrence of two or more unprovoked seizures at least 24 h apart. Epilepsies were classified according to their aetiology as idiopathic, cryptogenic or remote symptomatic, following the ILAE criteria. In particular, epilepsies were classified as remote symptomatic when they occurred in a patient with a history of a neurological deficit of pre-or perinatal origin or a prior neurological injury such as central nervous system infection, stroke or significant head trauma. 2 Therefore, this group included patients with global developmental delay/mental retardation and cerebral palsy. Classification of patients by epileptic syndrome was performed according to the revised 1989 ILAE classification with some modifications to include newly described syndromes. 3 A family history of unprovoked seizures was defined as seizures affecting a first-degree relative (parent or sibling). Global developmental delay was defined as a developmental quotient below 70% and mental retardation as an intelligence quotient Seizure 21 (2012) 266-272 bellow 70. Intelligence was clinically assessed when formal intelligence tests scores were not available. Motor deficit was considered present if there was hemiplegia, diplegia, quadriplegia or ataxia in the context of cerebral palsy or as a result of a central nervous system injury (e.g. infection, stroke or head trauma) that occurred later in life. Therapeutic regimen or schedule was considered to be any combination of antiepileptic drugs (AEDs) in mono-or polytherapy. A change in dosage was not considered a change in therapeutic regimen. To considered, a therapeutic regimen had to be appropriate (safe and effective) and adequately applied (taken at least in standard maintenance doses for a sufficient amount of time). Drugs considered inappropriate for the seizure type of the patient (e.g. ethosuximide for partial seizures) or withdrawn due to intolerable side effects were ignored for further analyses. Compliance was assessed by directly questioning the child's parents. If compliance was in doubt, it was verified by means of determining anti-epileptic drugs levels.
Categorisation of treatment outcome and classification of drug responsiveness of epilepsy were performed following ILAE recommendations. 1 Minor modifications and specifications were introduced to adapt definitions to our study. Treatment outcome was classified in three categories: (1) ''seizure freedom'': the patient was free of all types of seizures for the last 12 months or three times the longest interseizure interval (determined from seizures occurring within the past 12 months) prior to starting a new therapeutic regimen, whichever was longer; (2) ''treatment failure'': unable to achieve a ''seizurefree'' state on a given therapeutic regimen i.e., when a new therapeutic regimen had been initiated or when seizures recurred after starting a therapeutic regimen and the required time interval to consider the patient seizure-free had not elapsed; (3) ''undetermined'': no recurrences had occurred after starting a new therapeutic regimen but the required seizure-free interval had not elapsed (see Table 1 ).
In evaluating the efficacy of a therapeutic regimen, seizures related to attempted medication withdrawal were not taken into account. These were defined as recurrences that occurred after medication withdrawal but were not repeated after reinitiating the drug.
Drug responsiveness of epilepsy was classified in three classes: (1) ''drug-resistant epilepsy'': failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapy or in combination) to achieve seizure freedom; (2) ''drug-responsive epilepsy'': achievement of seizure freedom on the first or second AED regimen; (3) ''undefined'': failure of only one therapeutic schedule or ''treatment outcome'' of the second therapeutic regimen classified as undetermined. When a patient was ''seizure free'' and experienced one recurrence, the ''outcome'' of the individual drug was classified as ''undetermined'' and ''drug responsiveness'' as ''undefined''. If two seizures occurred, outcome to the individual drug was categorised as ''treatment failure'' and drug responsiveness remained ''undefined''. Epilepsy was redefined as ''drug resistant'' if an additional AED failed.
Cohort selection
Torrecá rdenas Hospital is the reference hospital of Almería province in Spain and has the only electroencephalogram (EEG) laboratory and paediatric neurology division in the province. Between June 1st, 1994 and May 1st, 2008 all patients younger than 14 years of age consecutively observed at our hospital for two or more newly diagnosed unprovoked seizures at least 24 h apart were enrolled in a prospective study. Patients with seizures limited to the neonatal period, patients with seizures due to inborn errors of metabolism or neurodegenerative disorders and children already on antiepileptic treatment or who had been previously examined in other centres were excluded. Consequently, all patients were directly referred by primary care paediatricians or were first observed in our emergency department.
The study was approved by the ethical committee of Torrecá rdenas Hospital and we obtained informed consent to participate for each patient.
Initial evaluation
A standard EEG was performed for each patient upon epilepsy diagnosis. If the standard EEG was normal, a sleep recording was performed. Computed tomography (CT) or magnetic resonance imaging (MRI) was performed at least in those cases with abnormal neurological examination findings, focal seizures, focal EEG abnormalities (except in the case of benign childhood epilepsy with centro-temporal spikes) or West syndrome. Because this is an observational study, the treating physician chose the AED to be used. Some patients were not treated with AEDs.
Follow-up
All patients were followed by personal interviews for at least at six to twelve months intervals until May 1st, 2010 (to allow for a minimum of a two-year follow-up) or until a three-year remission without an AED (i.e., three years with neither treatment nor relapses). The number and dates of recurrences were recorded at every visit.
Patients in remission were thereafter contacted by telephone until they achieved five years without anti-epileptic treatment. After that, patients were instructed to contact us if a relapse occurred. Otherwise, patients were considered to be in remission. We adopted this method to simplify the follow-up process because previous studies showed that recurrence risk beyond five years after medication withdrawal is very low. 4 Patients were followed for a maximum of 14 years. In most instances of persistent seizures, AEDs were pushed to the maximum tolerated doses before a trial with a new therapeutic regimen was considered. In cases when treatment failed due to lack of efficacy, the original drug was substituted or combination therapy was offered. In general, medication withdrawal was attempted after a two-year seizure-free period. Classification of treatment outcome and drug responsiveness of epilepsy was done retrospectively with prospectively obtained data regarding seizure recurrence and remission.
Analysis
The probability of developing drug-resistant epilepsy was calculated using Kaplan-Meier curves and percentages at two, six and ten years after diagnosis. All treatments initiated before May 1st, 2010 were taken into account for these analyses. Responses to different treatment schedules were calculated as percentages. For this latter analysis only treatments initiated before May 1st, 2008 were considered, to allow for a minimum of two years of follow-up. Calculations were performed by means of SPSS statistical software for Windows, version 15.0.
Results
General features of the sample
Five hundred and twenty patients were enrolled in the study. Nine children were lost to follow-up before completing a minimum follow-up of two years, and three patients died within two years of diagnosis. Consequently, 508 patients were followed for more than two years and constituted the study sample. Thereafter, another 26 patients were lost and six died. Twelve of the 26 (46%) lost cases were seizure free and without antiepileptic treatment for more than three years. Overall, we lost contact with only 6.7% (9 + 26) cases in the original sample.
Patients were followed for a mean of 90 months (SD 45, range 24-168). Out of the 508 patients, 390 (77%) were followed for more than four years, 301 (59%) for more than six years, 210 (41%) for more than eight years, 131 (26%) for more than ten years and 75 (15%) for more than 12 years.
The mean age at diagnosis was 4.9 years (SD 3.8). Ninety-four (18%) of the children were younger than one year old when they were diagnosed with epilepsy, 375 (74%) were between one and ten years of age and 39 (8%) were 11 years old or older. A total of 271 were male and 237 were female. Neuroimaging was performed in 438 (86%) patients: CT in 119, MRI in 207 and both in 112. Aetiology was remote symptomatic in 164 cases (32%), cryptogenic in 140 (28%) and idiopathic in 204 (40%).
Course and effectiveness of the first treatment
Forty-nine (9.6%) patients were not treated, and 459 received a first therapeutic regimen. The first AED, used in monotherapy, was valproic acid in 291, carbamazepine in 66, oxcarbazepine in 49, phenobarbital in 17, lamotrigine in five, vigabatrin in five, phenytoin in four, ethosuximide in three, clonazepam in two and levetiracetam in one. In 16 patients diagnosed with West syndrome, the first regimen consisted of oral corticoids or ACTH plus valproic acid.
The mean of the longest interseizure interval prior to starting treatment was 72 days (SD 130 
Categorisation of treatment outcome
Four hundred and fifty-nine patients were treated. Twenty-nine out of a total of 690 AEDs tested in mono-or polytherapy (4%) [95% CI: 2,6] were withdrawn due to unacceptable side effects and were not considered for further analysis. Table 2 shows the categorisation of treatment outcome. Table 3 shows the classification of drug responsiveness of epilepsy at two, six and ten years after diagnosis. Proportions in the table indicate probabilities of meeting criteria at each time point (not cumulative probabilities).
Classification of drug responsiveness of epilepsy
At first glance, it may seem inadequate to calculate the percentage of drug-resistant patients out of the total sample (including untreated patients). However, from an epidemiological point of view, to study the incidence of drug-resistant epilepsy in Table 2 Categorisation of treatment outcome. Classification was made with data at the end of the study period. Consequently, ''seizure freedom'' refers to a seizure-free period without further recurrences. % represents the number of patients classified in each category/total number of patients treated with this schedule. the general epileptic patient population, it is relevant to know the proportion of drug-resistant patients, not only out of the total number of treated patients but also out of the total number of epileptic patients. Eighty-one (18%) out of 459 treated patients experienced a recurrence after a seizure-free period. In this setting, to consider a patient drug resistant according to ILAE recommendations, the current AED and a second AED must have failed, ignoring any other AED previously utilised (see Section 2). With the objective of investigating the consequences of this recommendation, we recalculated the number of drug-resistant patients, this time taking into account all AED employed in a patient. As a result, 97 children met the criteria for drug-resistant epilepsy, the percentage of drug-resistant epilepsy calculated amongst treated patients rose to 21% [95% CI: 17,25], and the percentage amongst the total sample rose to 19% [95% CI: 16,22].
Clinical features of drug-resistant patients
See Tables 4 and 5 .
Temporal evolution of drug resistant epilepsy
Eighty-eight patients fulfilled the criteria of drug-resistant epilepsy. Forty-seven (53%) did so within 24 months, 58 (66%) within 36 months and 67 (76%) within 48 months of diagnosis.
Nineteen (22%) patients had a ''seizure-free period'' before meeting the criteria for drug-resistant epilepsy.
To calculate the probability of becoming seizure-free after having met the criteria for drug resistance, we only considered patients in whom three or more regimens were initiated. The main reason for not having attempted more regimens was that the current AED had not been considered a failure at the end of the study period. Sixty-seven out of 88 children with drug-resistant epilepsy tried three or more AED regimens: 37 (55%) [95% CI: 43,67] cases achieved a seizure-free period (defined according to ILAE criteria). 25 cases (37%) [95% CI: 25,49] achieved a seizurefree period without further recurrences. Note that these figures do not necessarily coincide with those in Table 2 The Kaplan-Meier estimate of the probability of attaining a seizure-free period without further recurrences until the end of the Table 3 Classification of drug responsiveness at 2, 6 and 10 years after an epilepsy diagnosis. Only patients with sufficient follow-up at each time interval were considered. a Total number (with switch to a third AED + without change to a third AED). b Total number (two therapeutic schedules but insufficient time + only one therapeutic regimen). 
Discussion
Although this is a hospital-based study, it was designed to obtain a representative sample of the general population. Additional details about the sample selection process and the clinical features of the first 343 patients of the cohort have previously been published. 5, 6 Another limitation of this study is that classification of treatment outcome and drug responsiveness of epilepsy was performed retrospectively. However, we do not think that this is a major problem because the prospective follow-up of the cohort was designed for a previous study with similar characteristics, 5, 6 and the criteria applied are not affected by subjective interpretations.
The lack of a broadly accepted definition of drug-resistant, refractory or intractable epilepsy has made it difficult to compare studies on this matter. For this reason, the consensus definition proposed by the ILAE 1 is welcomed. To our knowledge this is the first time that these criteria were employed in a field study; therefore, it is not surprising that we have encountered some practical problems applying it.
The first problem was the variable time interval required to consider a patient seizure-free; this interval may change over time even in the same patient. However, our study shows that it is one year for 81% of the cases and 2 years for 91%. Utilisation of a variable time interval may be more precise, but it significantly increases the computation time and is a potential source of errors. It may be more practical to employ a fixed time interval when dealing with a large number of patients in the context of an epidemiological study.
The second question had to do with when to consider an AED as failed. To test the effectiveness of an AED, the ILAE proposal only requires that it have been used in a clinically effective dose for ''enough time'', without further explaining what ''enough time'' means. However, it is common practice to push the AED to the maximum tolerated or recommended doses before considering it as failed. Our study shows that this practice results in 41% of patients becoming seizure-free. As this process may take months, it is not possible to know if the observed outcome is the effect of the higher dose and/or a consequence of the natural disease course. In any case, a significant proportion of patients treated with a given AED had a number of seizures, sometimes over a long time interval, whilst taking a specific treatment. In these cases it was difficult to choose between the maximum interseizure interval before initiating treatment or after initiating treatment as the basis to decide whether a patient was seizure free. It was also difficult to decide when a therapeutic regimen had failed. To make things easier, we chose to maintain the maximum interseizure pretreatment interval, and for epidemiological purposes, we classified a therapeutic regimen as treatment failure when a new regimen had been initiated or when seizures recurred once or more after starting a therapeutic regimen and at a given time interval (e.g., two years) the required time period to consider the patient seizure-free had not elapsed.
A third question is related to the fact that the classification scheme does not specify how recurrences related to attempted medication withdrawal should be managed. In accordance with the spirit of the proposal, we chose to ignore them because presumably, they are due to lack of AED efficacy.
Regarding the probability of response to the first and subsequent therapeutic schedules, we found that the probability of attaining seizure freedom was 65% with the first regimen. This figure is quite similar to the findings of a large, pragmatic, randomised controlled trial. 7, 8 The probability of achieving seizure freedom was 29% with the second, 27% with the third and 21% with the fourth and subsequent schedules (number of patients attaining seizure freedom with a treatment schedule/number of patients treated with this schedule). These last outcomes are considerably better than those in a previous study of adolescent and adults 9, 10 and slightly better than those observed in a previous study of the first 343 patients of our cohort. 6 These results show that patients with drug-resistant epilepsy according to the ILAE criteria still have a significant likelihood of entering in remission with subsequent treatment schedules (see below). The reported incidence of drug-resistant epilepsy in children ranges between 6% and 24%. 6, [11] [12] [13] [14] As expected, the incidence depends on the diagnostic criteria employed, which differ significantly between studies. Some used stringent criteria, which require a high frequency of seizures during a given length of time, and others used broader criteria that do not require a high seizure frequency. In two studies, refractoriness was defined as failure of more than two AEDs with an average of more than one seizure per month for !18 months and no more than three consecutive seizure-free months during this interval. In these studies, 9% 6 and 10% 13 of patients met the criteria for refractory epilepsy. Three other studies employing similar criteria reported figures of 6%, 12 8% 11 and 14%. 14 The variability in these studies does not appear to be related to minor differences in diagnostic criteria, but to different sample features and follow-up time. 6 On the other hand, the rate of drug-resistant epilepsy substantially increases when broader criteria are employed. One study defined refractoriness as ''no five-year remission ever during a follow-up of at least ten years'' and found a 19% rate of refractory epilepsy. 15 In a second study, the criterion was ''failure of two AEDs'', and the rate was 23%. 14 A third study used the criterion ''failure to reach a one-year terminal remission'', and the figure was 24%. 6 In short, the incidence of drug-resistant epilepsy in children ranges from 6 to 14% in studies that use stringent criteria and from 19 to 24% in studies that employ broader criteria. Some patients experienced a recurrence after a seizure-free period. In this setting, to consider a patient drug-resistant according to ILAE recommendations, the current AED and a second AED must have failed, ignoring any other AED previously utilised (see Section 2). This approach slightly reduces the incidence of drug-resistant epilepsy from 19% to 17%.
Regarding clinical characteristics of drug-resistant patients, we observed predominance in younger children (62% younger than four years old) and a high prevalence of associated handicaps (global development delay/mental retardation and/or motor deficit in 73%). With respect to aetiology, 40% of the cases had a normal neurological examination and no identifiable structural lesions on neuroimaging, 18% had no identifiable structural cause for epilepsy but had nonspecific global developmental delay/ mental retardation before epilepsy onset, and 42% had a definite cause of epilepsy. Although the causes were heterogeneous, the most frequent were cerebral malformations (16% of the drugresistant epilepsies) and pre-or perinatal hypoxic-ischaemic lesions (10%). It was possible to diagnose a specific epileptic syndrome in only 32% of the cases. Syndromes that usually have a good outcome, such us benign childhood epilepsy with centrotemporal spikes, Panayiotopoulos syndrome, myoclonic epilepsy in infancy, childhood absence epilepsy and juvenile myoclonic epilepsy, were diagnosed in 12% of the cases, and syndromes with a known poor prognosis, including West syndrome, Lennox syndrome, Dravet syndrome and epilepsy with myoclonic-atonic seizures, accounted for another 20%. The rest were ill-defined cases with predominance of epilepsies with focal seizures and remote symptomatic aetiology (35%). A previous study that defined refractory epilepsy as the failure of two AEDs found similar results.
14 Another important clinical aspect is seizure frequency: 73% of our cases had one or more seizures per month, but 8% only had one to three per year. It is evident that the second group of cases does not pose the same therapeutic problems as those with very frequent seizures.
Drug responsiveness is a dynamic process; some patients may attain seizure freedom and then become drug resistant, whilst others may enter remission after having fulfilled the criteria for drug resistance. In the present study, 22% of drug-resistant patients had a previous seizure-free period. On the other hand, 51% later attained a seizure-free period and 37% entered a seizure-free period without further recurrences. At the end of the study, 19% of our drug-resistant cases were seizure free for more than four years, and 20% were without antiepileptic treatment. A recent study in children that also defined drug resistance as failure of two AEDs found similar results. 16 Nevertheless, remission was attained earlier in our study: we found a probability of achieving a period of seizure freedom (one year in most of the cases) without further recurrences of 23%, 29% and 37% at three, four and five years, respectively, whereas the other study had proportions of patients entering and remaining in one-year remission of 19%, 40% and 47% at five, ten and 12 years, respectively. In any case, it must be emphasised that a significant proportion of drug-resistant epilepsies defined as the failure of two AEDs may later enter remission. This is an important point when surgical treatment is under consideration. However, this proportion is considerably lower when failure of three antiepileptic regimens or failure of two antiepileptic regimens plus a high frequency of seizures for a given length of time are required for a definition of drug-resistance. We previously found that after failure of three antiepileptic regimens, only 15% of patients were seizure free for more than one year at last contact. In this study, drug-resistant epilepsy was defined as failure of !2 AEDs plus an average of more than one seizure per month for !18 months and no more than three consecutive seizure-free months during this interval. 6 In patients fulfilling these criteria, only 7% later had a remission of at least two years. In another study employing the same criteria, only 20% of patients experienced a remission of at least one year, and 13% were in remission for at least one year at last contact.
14 Some patients become drug resistant after a variable time interval, so the cumulative probability of developing drugresistant epilepsy increases with time. In our sample, this probability was 10%, 19% and 23% at two, six and ten years, respectively. Conversely, there are patients who enter remission after having fulfilled drug-resistance criteria. Consequently, the probability of meeting criteria for drug resistance at a time point remains relatively constant over time: 11%, 11% and 13% at two, six and ten years from diagnosis, respectively. This is an important aspect to consider when interpreting incidence and prevalence studies.
In conclusion, the present ILAE's definition of drug-resistant epilepsy is a broad criteria definition. Compared with definitions with more stringent criteria, it yields a higher incidence of drugresistant epilepsy and includes patients with less frequent seizures. A significant proportion of the cases meeting the ILAE criteria eventually enter remission. Additional criteria requiring high seizure frequency for a given length of time or failure of three antiepileptic regimens may better identify patients with truly drug-resistant epilepsy. Perhaps the broader definition may be more suitable for selecting patients for thorough evaluations, and the most restrictive one may be more appropriate for therapeutic considerations.
